Oncimmune Holdings PLC PDMR Dealing (1888A)
September 21 2022 - 9:16AM
UK Regulatory
TIDMONC
RNS Number : 1888A
Oncimmune Holdings PLC
21 September 2022
Oncimmune Holdings plc
("Oncimmune" or the "Company")
PDMR Dealing
Oncimmune Holdings plc (AIM: ONC.L), the leading global
immunodiagnostics group, has been notified that Dr Adam Mark Hill,
PDMR and Chief Executive Officer, today purchased 8,005 ordinary
shares of GBP0.01 each in the Company ("Ordinary Shares") for
GBP0.624599 per share.
Following this transaction, Dr Hill has a total interest in the
Company of 73,872 Ordinary Shares, representing approximately 0.11
per cent of the Company's issued share capital of 69,475,480.
In addition, Dr Hill holds options over a total of 3,490,862
Ordinary Shares, representing approximately 5.02 per cent of the
Company's issued share capital.
This announcement, including the notification below, is made in
accordance with the requirements of Article 19 of the UK Market
Abuse Regulation.
Notification and public disclosure of transactions by person
discharging managerial responsibilities and persons closely
associated with them:
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Dr Adam Mark Hill
------------------------------------- --------------------------------------
Reason for the notification
2
-----------------------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------------------- --------------------------------------
b) Initial notification Initial Notification
/Amendment
------------------------------------- --------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name Oncimmune Holdings plc
------------------------------------- --------------------------------------
b) LEI 213800HCYIWT6YPI1I02
------------------------------------- --------------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------------
a) Description of the Ordinary Shares of GBP0.01 each
financial instrument,
type of instrument
Identification code ISIN: GB00BYQ94H38
b) Nature of the transaction Purchase of Ordinary Shares
------------------------------------- --------------------------------------
c) Price(s) and volume(s)
------------------- --------------
Price(s) Volume(s)
------------------- --------------
GBP0.624599 8,005
-------------------------------------------------------------- --------------
d) Aggregated information N/A - single transaction
- Aggregated volume
- Price
e) Date of the transaction 21 September 2022
------------------------------------- --------------------------------------
f) Place of the transaction London Stock Exchange, AIMX
------------------------------------- --------------------------------------
For further information:
Oncimmune Holdings plc
Dr Adam M Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Singer Capital Markets (Nominated Adviser and Joint Broker)
Aubrey Powell, Harry Gooden, George Tzimas, James Fischer
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Nigel Barnes, Erland Sternby
+44 (0)20 3705 9321
Investor Relations:
John Goold
IR@oncimmune.com
About Oncimmune
ImmunoINSIGHTS Service Business
Oncimmune is a leading immunodiagnostics developer, primarily
focused on the growing fields of immuno-oncology, autoimmune
disease and infectious diseases. The ImmunoINSIGHTS service
business leverages Oncimmune's technology platform and
methodologies across multiple diseases, to offer life-science
organizations actionable insights for therapies across the
development and product lifecycle. Our core immune-profiling
technology is underpinned by our library of over eight thousand
immunogenic proteins, one of the largest of its kind. This helps
identify trial participants and patients into clinically relevant
subgroups, enabling development of targeted and more effective
treatments.
Oncimmune's ImmunoINSIGHTS service business is based at the
Company's discovery research centre in Dortmund, Germany. The
business platform enables life science organizations to optimize
drug development and delivery, leading to more effectively targeted
and safer treatments for patients.
The ImmunoINSIGHTS development team is based in the US and
Europe and Oncimmune is seeking to replicate the Dortmund facility
in the US in the medium term.
EarlyCDT Product Business
Oncimmune's immunodiagnostic technology, EarlyCDT, can detect
and help identify cancer on average four years earlier than
standard clinical diagnosis. Our lead diagnostic test, EarlyCDT
Lung, targets a vast market estimated to grow to GBP3.8bn by 2024.
With over 200,000 tests already performed for patients worldwide
and its use being supported by peer reviewed data in over 12,000
patients, we are poised to become an integral component of future
lung cancer detection programs, globally.
Oncimmune's diagnostic products business is located at its
laboratory facility in Nottingham, UK.
For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHUAAORUSUKUAR
(END) Dow Jones Newswires
September 21, 2022 09:16 ET (13:16 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2023 to Apr 2024